Tin tức & Cập nhật

Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer
Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer
12 Sep 2022

In the treatment of patients with HER2-positive locally advanced breast cancer, adding pyrotinib to trastuzumab plus chemotherapy in the neoadjuvant setting yields high response rates while being safe, according to the results of NeoATP trial.

Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer
12 Sep 2022
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
11 Sep 2022
Trifluridine/tipiracil add-on to bevacizumab safe, effective for mCRC
Trifluridine/tipiracil add-on to bevacizumab safe, effective for mCRC
09 Sep 2022

In patients with metastatic colorectal cancer (mCRC), using trifluridine/tipiracil with bevacizumab is a safe and effective treatment for refractory disease, a recent study has found.

Trifluridine/tipiracil add-on to bevacizumab safe, effective for mCRC
09 Sep 2022
Low-dose methotrexate-related melanoma risk considered negligible
Low-dose methotrexate-related melanoma risk considered negligible
09 Sep 2022
Nine metabolic biomarkers can detect gastric cancer
Nine metabolic biomarkers can detect gastric cancer
09 Sep 2022 bởiTristan Manalac

Gastric cancer (GC) patients show an altered metabolic profile as compared with healthy individuals, a recent China study has found. A biomarker panel monitoring for nine metabolites can facilitate timely detection of GC.

Nine metabolic biomarkers can detect gastric cancer
09 Sep 2022
CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases
CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases
09 Sep 2022 bởiSarah Cheung

First-line treatment of ALK-positive non-small-cell lung cancer (NSCLC) with lorlatinib improves progression-free survival (PFS) and reduces central nervous system (CNS) progression vs crizotinib, regardless of presence or absence of baseline brain metastases (BM), a post hoc analysis of the phase III CROWN trial has shown.

CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases
09 Sep 2022